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Minimally Invasive Saliva Testing to Monitor Norovirus 
Infection in Community Settings
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and Molecular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru; 5Institute for Interdisciplinary Salivary Bioscience, University of California, Irvine; 6Department 
of Pediatrics, Johns Hopkins University School of Medicine, 7Department of Acute and Chronic Care, Johns Hopkins University School of Nursing, 8Department of Population, 
Family, and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, and 9Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, 
Maryland; 10Asociación Benéfica Prisma, Iquitos, Perú; 11Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and 12National 
Calicivirus Laboratory, Centers for Disease Control and Prevention, Atlanta, Georgia
Background. Norovirus is a leading cause of acute gastroenteritis worldwide. Routine norovirus diagnosis requires stool collec-
tion. The goal of this study was to develop and validate a noninvasive method to diagnose norovirus to complement stool diagnostics 
and to facilitate studies on transmission.
Methods. A multiplex immunoassay to measure salivary immunoglobulin G (IgG) responses to 5 common norovirus genotypes 
(GI.1, GII.2, GII.4, GII.6, and GII.17) was developed. The assay was validated using acute and convalescent saliva samples collected 
from Peruvian children <5 years of age with polymerase chain reaction (PCR)–diagnosed norovirus infections (n = 175) and controls 
(n = 32). The assay sensitivity and specificity were calculated to determine infection status based on fold rise of salivary norovirus 
genotype-specific IgG using norovirus genotype from stool as reference.
Results. The salivary assay detected recent norovirus infections and correctly assigned the infecting genotype. Sensitivity was 
71% and specificity was 96% across the evaluated genotypes compared to PCR-diagnosed norovirus infection.
Conclusions. This saliva-based assay will be a useful tool to monitor norovirus transmission in high-risk settings such as day-
care centers or hospitals. Cross-reactivity is limited between the tested genotypes, which represent the most commonly circulating 
genotypes.
Keywords. norovirus; saliva; multiplex immunoassay; noninvasive diagnostics; MAL-ED.
 
Norovirus causes an estimated 19–21 million cases of acute 
gastroenteritis (AGE) in the United States  each year, leading 
to 56 000–71 000 hospitalizations and 570–800 deaths, mostly 
among young children and older adults. Norovirus is the lead-
ing cause of severe AGE among medical care–seeking US chil-
dren <5 years of age, and a principal cause of AGE outbreaks 
on cruise ships and in preschools, hospitals, and long-term care 
facilities [1–5].
The current gold standard for norovirus laboratory diag-
nosis involves viral nucleic acid extraction from fecal samples 
and quantitative reverse-transcription polymerase chain reac-
tion (RT-qPCR) for genogroup I  (GI) and GII, followed by 
conventional RT-PCR and sequencing of a partial region of the 
capsid and polymerase genes and subsequent sequence-based 
genotyping of the virus [6–8].
Stool sample collection and testing is a feasible method in 
clinical settings where patients with severe AGE present seeking 
care; however, patients and family members are inconvenienced 
by stool collection and handling and often do not provide appro-
priate samples [9]. An alternative approach to diagnose infection 
is measuring pathogen-specific antibody levels in blood [10]. 
But blood collection is invasive, usually requires clinically 
trained personnel, and has practical constraints among young 
children. More convenient testing methods would greatly 
increase the coverage of diagnostic testing in epidemiologic 
studies, outbreak investigations, and disease surveillance.
Saliva collection is minimally invasive, does not require clin-
ical personnel, and can be implemented easily in any setting 
including remote areas and community-based settings [11–13]. 
Saliva harbors pathogen-specific immunoglobulin A (IgA) and 
immunoglobulin G (IgG) antibodies, and immunoassays based 
on saliva can detect pathogen exposure with similar sensitiv-
ity and specificity as blood-based immunoassays in adults [13]. 
Several studies have shown an increase in norovirus-specific 
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IgG and IgA in saliva postchallenge with Norwalk virus (GI.1) 
and Snow Mountain virus (GII.2) [14–17]. Griffin et al demon-
strated that multiplex immunoassays for salivary antibodies to 
a variety of waterborne pathogens including 3 norovirus gen-
otypes (GI.1, GII.4, and GII.9) could detect a GII.4 infection 
in an adult volunteer and that salivary immunoassays to detect 
IgG and IgA against Norwalk virus could correctly identify 3 
infected and 4 noninfected volunteers in a challenge study 
[16, 17]. However, salivary norovirus genotype-specific IgG 
responses among children <5 years of age with PCR-diagnosed 
norovirus infections have not been described previously.
Our goal was to develop and validate a multiplex norovirus 
assay to measure antibody responses in saliva to 5 common 
norovirus genotypes (GI.1, GII.2, GII.4, GII.6, and GII.17) 
and to describe the salivary IgG response to those genotypes 
among children with stool-diagnosed norovirus infection and 
controls. We aimed to (1) investigate the change in norovirus 
genotype-specific IgG in saliva between the acute and convales-
cent phase of norovirus infection and (2) determine the salivary 
norovirus IgG assay’s sensitivity and specificity to diagnose nor-
ovirus infection at the genotype level compared to molecular 
diagnosis by RT-PCR of the infecting genotype in stool in order 
to provide a practical tool for the evaluation of norovirus out-
breaks and study of transmission.
MATERIALS AND METHODS
Study Design and Sample Collection
For this study, data and samples were collected from children 
<5 years of age who participated in 2 research studies in Peru. 
One study was a case-control study designed to evaluate the 
etiology of medically attended AGE in children <5  years of 
age following nationwide rotavirus vaccine implementation 
in Peru. Children were enrolled at the Instituto Nacional de 
Salud Del Niño in Lima, Peru, from October 2013 through 
May 2015. Children presenting with symptoms of AGE were 
defined as cases; children seeking care unrelated to AGE and 
without a diarrheal episode within the past 30 days were defined 
as controls. AGE was defined according to the World Health 
Organization initiative to estimate the global burden of food-
borne diseases [18]. Caregivers provided demographic and 
symptom information and study personnel collected a stool 
and a saliva sample (SalivaBio Children’s Swab, Salimetrics). 
Children with acute norovirus infections (defined as a stool 
sample positive for norovirus GI or GII by RT-PCR) were vis-
ited by study personnel at least 21 days later to collect a con-
valescent phase saliva sample. Timing for convalescent phase 
saliva collection was informed by a previous study describing 
that 83% of infected individuals had a ≥4-fold increase in sali-
vary IgG 21 days post–norovirus challenge and that salivary IgG 
continued to rise through 21 days postchallenge [19]. Children 
enrolled as controls provided 1 saliva sample. Preliminary anal-
yses of stool samples from children enrolled into this study 
showed that 36.2% of children enrolled as cases and 12.4% of 
children enrolled as controls had norovirus-positive stools.
Because this study was not designed to compare the change 
in antibody against norovirus between cases and controls (ie, 
no second saliva sample was collected among controls), addi-
tional samples collected among children who participated in 
the Etiology, Risk Factors, and Interactions of Enteric Infections 
and Malnutrition and the Consequences for Child Health and 
Development (MAL-ED) study in Iquitos, Peru, were included 
in the analysis. The MAL-ED birth cohort study has been 
described in detail previously [20–23]. A  subset of children 
who participated in the MAL-ED study in Iquitos provided 
monthly and diarrhea-triggered stool samples and weekly saliva 
samples (Oracol saliva swab, Malvern Medical Development) 
between May and September 2015. Children in the MAL-ED 
birth cohort were approximately 4–5  years old during the 
sample collection period. To match the Lima study design, 2 
saliva samples from each child that were collected during the 
acute and convalescent phase of infection or the closest avail-
able sampling time points were included in the analysis. More 
specifically, from children with norovirus infection during 
the 4-month sampling period, the last saliva sample before a 
stool-confirmed norovirus infection and a second saliva sam-
ple collected 4 weeks later or the closest available were selected 
(cases). For children without norovirus infection during the 
sampling period (defined as monthly stool samples norovirus 
GI and GII negative by RT-qPCR), 2 saliva samples that were 
collected 4 weeks apart were selected randomly (controls). 
This study was approved by Asociación Benéfica Prisma and 
Universidad Peruana Cayetano Heredia (Lima, Peru) and the 
Johns Hopkins Bloomberg School of Public Health Institutional 
Review Board (Baltimore, Maryland).
Norovirus Genotyping From Stool Samples
RNA was extracted from a 10% wt/vol suspension of stool in 
phosphate-buffered saline using the Qiagen QIAmp viral RNA 
kit according to the manufacturer’s instructions and tested for 
norovirus GI and GII by RT-qPCR [24]. Samples were consid-
ered positive if the cycle threshold for the sample was ≤37 for 
norovirus GI and ≤39 for GII. For positive samples, a partial 
region of the capsid gene (region C) was amplified. Amplicons 
were then purified and sequenced. The generated sequences 
were genotyped using the online NoroNet sequence typing tool 
[25, 26] or using http://norovirus.phiresearchlab.org/.
Multiplex Immunoassay for Norovirus Genotype-Specific IgG in Saliva
Virus-like particles (VLPs) for 5 norovirus genotypes (GI.1, 
GII.2, GII.4, GII.6, and GII.17) were kindly provided by Dr 
Robert Atmar and covalently coupled to 5 magnetic micro-
particle sets (MagPlex microspheres, Luminex) as described 
previously [13]. Coupling of VLPs to beads was confirmed 
using monoclonal mouse antibodies against GI.1 and GII.4 
(Maine Biotechnology Services) followed by R-phycoerythrin 
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(PE)–labeled anti-mouse antibody and convalescent sera 
from patients with known GI.1 and GII.4 infections fol-
lowed by PE-labeled anti-human IgG antibody (Jackson 
ImmunoResearch Laboratories) and revealed a fluorescent sig-
nal of >20 000 mean fluorescence intensity (MFI).
Saliva samples were centrifuged (5 minutes at 10 000g, 20°C), 
and 10  μL of saliva supernatant was added to 40  μL of assay 
buffer (phosphate-buffered saline with 0.05% Tween20 and 1% 
bovine serum albumin) containing 2000 beads of each bead 
set (GI.1, GII.2, GII.4, GII.6, and GII.17 VLPs) per microplate 
well. The plate was covered and incubated at room temperature 
for 1 hour on a plate shaker at 500  rpm. Beads were washed 
3 times, 50 μL of PE-labeled anti-human IgG diluted 1:100 in 
assay buffer was added, and the plate was incubated for 1 hour 
on a plate shaker at 500 rpm. Beads were again washed and were 
suspended in 100 μL of sheath fluid (Luminex), and the fluores-
cence signal was measured on a Bio-Plex 200 instrument (Bio-
Rad). A subset (~10%) of saliva samples was tested in duplicate 
to determine intra-assay variability, and 2 blanks (assay buffer) 
were included on each plate for background subtraction.
Statistical Analysis
Receiver operating characteristic (ROC) analyses based on 
logistic regression models were used to determine if (1) the fold 
rise of the salivary norovirus genotype-specific IgG response, 
(2) the difference between acute and convalescent IgG response, 
or (3) the difference between acute and convalescent IgG 
response divided by the time in days since the first sample col-
lection (slope) would correlate best (highest area under the 
curve [AUC]) with infection status. Logistic regression models 
were used to estimate the association between the fold rise of 
norovirus genotype-specific IgG MFI in convalescent (or sec-
ond) samples compared to acute phase (or first) saliva samples 
and RT-PCR–confirmed norovirus genotype infection status. 
Models were adjusted for all measured salivary IgG responses 
in the same model to account for potential cross-reactivity of 
salivary IgG to other genotypes included in the assay.
Several threshold definitions to determine infection status 
were explored and the sensitivity and specificity compared to 
the stool-diagnosed norovirus genotype were calculated. This 
included defining infection with genotypes GI (GI.2, GI.3, and 
GI.5 were combined as GI), GII.4, GII.6, or GII.17 as (1) a fold 
rise in genotype-specific IgG that is larger than the 95th per-
centile among controls, and (2) a >2-fold and (3) a >3-fold rise 
in salivary IgG against the norovirus genotype that elicited the 
highest immune response.
RESULTS
Among the Lima cohort, 386 saliva samples from 235 chil-
dren were collected. Children enrolled in Lima with stool-con-
firmed norovirus infection (cases; n  =  151) provided a stool 
and saliva sample at their first visit (acute phase) and a second 
(convalescent phase) saliva sample on average 1  month later 
(median, 32 [range, 10–195] days). Children without norovirus 
infection (controls; n = 84) provided a single saliva sample. The 
MAL-ED cohort of 77 children in Iquitos, Peru, provided 1004 
saliva samples and 333 stool samples. Children with at least 1 
norovirus infection (stool sample positive for norovirus GI or 
GII by RT-qPCR) were defined as cases (41/77 [53%]); children 
without stool-confirmed norovirus infection over the 4-month 
study period were defined as controls (36/77 [47%]).
Sample Selection
Among the Lima cohort, controls (n = 84) were excluded from 
the analysis because no second saliva sample was available and 
therefore the fold rise in genotype-specific IgG could not be cal-
culated. Additionally, 2 cases were excluded because of insuf-
ficient saliva volume (<10 μL). Similarly, among the MAL-ED 
cohort, 20 children were excluded from the analysis because no 
saliva sample was available either before or at least 10 days after 
the stool-diagnosed norovirus infection (16 cases) or because 
only 1 saliva sample was available (4 controls). The sample selec-
tion process and resulting sample numbers used in the follow-
ing analysis are described in Table 1. The mean age of children 
with stool-confirmed norovirus infection (Lima and MAL-ED 
cases combined, n = 175) was 23 months (range, 2–59 months) 
and of children without norovirus infection (MAL-ED controls, 
n = 32) was 44 months (range, 39–49 months). A slightly higher 
mean age among MAL-ED controls was expected due to the 2 
different study designs. Children aged <5 years were eligible for 
enrollment into the Lima study cohort, whereas the MAL-ED 
birth cohort children were 3–5  years old during the sample 
collection period. For the following analyses, cases from both 
cohorts and controls from the MAL-ED cohort were combined.
Norovirus Genotype Distribution
The norovirus genotype distribution among children with nor-
ovirus infection is presented in Figure 1. Norovirus GII.4 was 
the predominant genotype (n = 101 [57%]), followed by gen-
otypes GI.3 (n = 23 [13%]), GII.17 (n = 20 [11%]), and GII.6 
(n = 15 [9%]).
Norovirus Genotype-Specific IgG Response in Saliva
The median anti-GI.1, anti-GII.4, anti-GII.6, and anti-GII.17 IgG 
MFI was higher in convalescent samples compared to acute sam-
ples among children with GI, GII.4, GII.6, and GII.17 infections, 
respectively (Table 2). The median fold rise of anti-GI.1, anti-GII.4, 
anti-GII.6, and anti-GII.17 IgG of convalescent to acute samples 
was also higher among children infected with the respective gen-
otype (27 GI, 101 GII.4, 15 GII.6, and 20 GII.17 cases) compared 
to children infected with other genotypes and controls, suggesting 
that norovirus infections elicit a genotype-specific IgG response 
that can be measured in saliva. However, the standard deviation of 
the salivary IgG response between children with the same infect-
ing genotype and among controls was high. We did not observe 
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associations between the fold rise in salivary anti-norovirus IgG 
among GI, GII.4, GII.6, and GII.17 cases and age.
Intra-assay Variability
The average intra-assay variability (coefficient of variation 
[CV%]) to detect anti-GI.1, GII.2, GII.4, GII.6, and GII.17 IgG 
was 3.5%, 4.2%, 2.3%, 3.4%, and 4.8%, respectively. These values 
represent the average CV% of 30 saliva samples (~7.5% of all 
samples) that were each measured in duplicate. The observed 
variability lies below assay precision criteria (±15% CV) recom-
mended for commercial assays [27].
ROC Curves
Figure  2 shows the ROC curves based on logistic regression 
models to estimate the association between (1) fold rise of GI-, 
GII.2-, GII.4-, GII.6-, and GII.17-specific IgG MFI in conva-
lescent compared to acute samples; (2) difference in geno-
type-specific IgG MFI; and (3) difference in genotype-specific 
IgG MFI divided days since first sample collection and stool-di-
agnosed infection outcome.
The fold rise in salivary norovirus IgG yielded the highest 
AUC for each outcome (GI, GII.4, GII.6, and GII.17 infection 
by RT-PCR from stool) and was therefore selected for further 
assay validation.
Association Between Fold Rise in Salivary Genotype-Specific IgG MFI 
and PCR-Diagnosed Genotype
We estimated associations between fold rise in genotype-specific 
IgG MFI in convalescent (or second samples among controls) 
compared to acute samples (or first samples among controls) 
and GI, GII.4, GII.6, and GII.17 infection status (Table 3). Odds 
ratios in Table 3 compare the fold rise in genotype-specific IgG 
among cases with one genotype infection to cases with different 
genotype infections and to controls.
The odds of infection with the respective genotype increase 
24- to 91-fold for every log10 unit increase in the genotype-spe-
cific IgG MFI fold rise variable when all genotype-specific IgG 
MFI responses (fold rise) represented in the multiplex assay 
were included in the model. However, a rise in anti-GII.2 IgG 
was also associated with higher odds for GI infection (Table 3), 
suggesting cross-reactivity between salivary anti-GI IgG and 
GII.2 VLPs used in this assay.
Sensitivity and Specificity of the Salivary Norovirus Genotype IgG Assay 
Compared to RT-PCR Diagnosis From Stool
Multiple threshold definitions to discriminate cases from noncases 
and controls were explored and assay sensitivity and specificity 
were calculated using the RT-PCR–diagnosed norovirus genotype 
as reference. Thresholds explored to discriminate children with 
GI.2
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Figure 1. Norovirus genotype distribution among children presenting with acute 
gastroenteritis (n  =  149) at a children’s hospital in Lima, and among children in 
Iquitos (n = 25), Peru, 2014–2015. One child was infected with 2 genotypes (GI.3 
and GII.22).
Table 1.  Sample Selection Criteria for Inclusion in Analysis of Children With and Without Norovirus Infection in Lima and Iquitos, Peru, 2014–2015
Sample
Lima Cohort Iquitos Cohort Total
Cases Controls Combined Cases Controls Combined
Samples collected, No.
 Children 151 84 235 41 36 77 312
 Saliva samples 302 84 386 529 475 1004 1390
 Stool samples 151 84 235 180 153 333 568
Samples included in 
analysisa
 Children 149 none 149 25b 32 57 206
 Saliva samples 298 none 298 52 64 116 414
 Stool samples 149 none 149 26 32 58 207
aInclusion criteria for analysis: ≥2 saliva samples with ≥10 µL volume available per child; saliva samples collected ≥10 days apart. Cases: first saliva sample collected ≤3 days prior to norovi-
rus-positive stool sample. Controls: first saliva sample collected ≤3 days prior to norovirus-negative stool sample.
bOne child contributed 4 saliva samples and 2 norovirus-positive stools (different genotypes) collected >1 month apart.
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Table 2. Norovirus Genotype-Specific Salivary Immunoglobulin G Response in Acute and Convalescent Saliva Samples From Children With GI, GII.4, GII.6, 
and GII.17 Infections Compared to Children With Other Norovirus Genotype Infections and Controls
Assay Analyte Sample Group No. First (Acute) Sample, MFI
Second (Convalescent) 
Sample, MFI Days Since First Sample
Fold Rise (Convalescent/ 
Acute)
Anti-GI.1 IgG GI cases 27 293 (941) 1605 (5193) 29 (30) 4 (18)
Non-GI cases 148 61 (1357) 38 (1671) 31 (32) 1 (11)
Controls 32 505 (2003) 560 (821) 28 (14) 1 (5)
Anti-GII.2 IgG GII.2 cases none NA NA NA NA
Non-GII.2 cases 175 68 (923) 135 (2052) 30 (31) 2 (22)
Controls 32 878 (1122) 506 (1924) 28 (14) 1 (1)
Anti-GII.4 IgG GII.4 cases 101 67 (817) 2139 (4858) 32 (34) 30 (134)
Non-GII.4 cases 74 577 (2591) 713 (2934) 29 (26) 1 (57)
Controls 32 1641 (1945) 1706 (3042) 28 (14) 1 (2)
Anti-GII.6 IgG GII.6 cases 15 46 (456) 1447 (2688) 26 (34) 15 (191)
Non-GII.6 cases 160 327 (3745) 715 (4312) 31 (31) 1 (28)
Controls 32 3542 (4002) 2796 (4388) 28 (14) 1 (2)
Anti-GII.17 IgG GII.17 cases 20 115 (490) 281 (1015) 34 (18) 3 (34)
Non-GII.17 cases 155 59 (1436) 82 (1958) 30 (33) 1 (13)
Controls 32 596 (1494) 511 (1513) 28 (14) 1 (3)
Data are presented as median (standard deviation). Data from 175 cases with norovirus infection (149 from Lima cohort and 26 from the Etiology, Risk Factors, and Interactions of Enteric 
Infections and Malnutrition and the Consequences for Child Health and Development [MAL-ED] cohort) and from 32 controls (MAL-ED cohort only) were included in this analysis.
Abbreviations: IgG, immunoglobulin G; MFI, mean fluorescence intensity; NA, not applicable.
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Figure 2. Receiver operating characteristic (ROC) with corresponding area under the curve (AUC) of the multiplex assay for salivary norovirus genotype-specific immuno-
globulin G to diagnose GI, GII.4, GII.6, and GII.17 infections among children <5 years of age in Lima and Iquitos, Peru, 2014–2015. Data from 175 cases with norovirus infection 
(149 from Lima cohort and 26 from Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development 
[MAL-ED] cohort) and from 32 controls (MAL-ED cohort only) were included in this analysis.
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norovirus at the genotype level and without infection included (1) 
a fold rise in salivary norovirus genotype-specific IgG larger than 
the 95th percentile of the fold rise among controls; (2) if largest 
fold rise is >2-fold; and (3) if largest fold rise is >3-fold (Table 4).
Case definitions (1) and (2) resulted in the highest sensitiv-
ity; however, using case definition 1, the specificity to diagnose 
GII.2, GII.6, and GII.17 infections was low (57%–76%). Case 
definition 2 resulted in the overall highest sensitivity (71%) and 
specificity (96%).
DISCUSSION
We developed a multiplex assay to measure IgG responses to 
5 norovirus genotypes in saliva. The assay was validated using 
acute and convalescent phase saliva samples collected from 175 
children with confirmed norovirus infections and from 32 chil-
dren without recent infection. The average sensitivity and spec-
ificity of the assay was 71% and 96%, respectively, compared 
with PCR diagnosis from stool.
The median convalescent phase norovirus genotype-specific 
IgG MFI was similar among children with or without a noro-
virus-positive stool, suggesting that most “controls” have been 
exposed to norovirus in the past. This finding is consistent with 
epidemiological studies that have demonstrated that children in 
Peru experience at least 1 GII infection by the age of 12 months 
and 1 GI infection by 24 months [20]. Hence, in highly endemic 
settings it is not feasible to apply anti-norovirus IgG MFI cut-
offs to discriminate “seropositive” from “seronegative” samples 
based on a single time point, as most children have experienced 
multiple norovirus infections by the time they reach 5 years of 
age. It may, however, be possible to design a salivary norovirus 
assay to measure the acute phase IgA response in a single saliva 
sample [28]. The magnitude of the anti-norovirus IgA response 
may vary by child age and will vary by time since infection. In 
this highly endemic study setting, we focused only on the sali-
vary IgG response, because we expected that a large proportion 
of children would experience a secondary immune response 
reflected by a rise in anti-norovirus IgG rather than a primary 
immune response reflected by a rise in anti-norovirus IgA.
We explored multiple cutoff definitions for immunoconver-
sion as a proxy of previous infection and calculated the corre-
sponding assay sensitivity and specificity to correctly identify 
the infecting norovirus genotype compared to PCR-based 
Table  3. Association Between Fold Rise of Genotype-Specific Immunoglobulin G Mean Fluorescence Intensity to 5 Norovirus Genotypes Following 
Infection and Reverse-Transcription Polymerase Chain Reaction–Diagnosed Genotype Among Children <5 Years of Age in Lima and Iquitos, Peru, 2014–2015
Norovirus Genotype Infection Status No. No. Positive OR (95% CI) P Value
GI 207 27
  Fold rise in salivary anti-GI IgG 56.2 (11.1–283.9) < .001
  Fold rise in salivary anti-GII.2 IgG 22.3 (1–488.6) .049
  Fold rise in salivary anti-GII.4 IgG 0.1 (0–.4) .002
  Fold rise in salivary anti-GII.6 IgG 0.6 (.2–2.7) .538
  Fold rise in salivary anti-GII.17 IgG 0.0 (.0–.6) .028
GII.4 207 101
  Fold rise in salivary anti-GI IgG 0.6 (.2–1.4) .220
  Fold rise in salivary anti-GII.2 IgG 0.1 (0–1.3) .080
  Fold rise in salivary anti-GII.4 IgG 90.5 (24.2–338.6) < .001
  Fold rise in salivary anti-GII.6 IgG 0.1 (0–.2) < .001
  Fold rise in salivary anti-GII.17 IgG 4.8 (.4–56.9) .213
GII.6 207 15
  Fold rise in salivary anti-GI IgG 0.5 (.1–2.2) .375
  Fold rise in salivary anti-GII.2 IgG 7.9 (.4–143.8) .164
  Fold rise in salivary anti-GII.4 IgG 0.2 (.1–.5) .002
  Fold rise in salivary anti-GII.6 IgG 24.3 (6.3–94.1) < .001
  Fold rise in salivary anti-GII.17 IgG 0.1 (0–1.7) .1
GII.17 207 20
  Fold rise in salivary anti-GI IgG 0.2 (.1–.7) .008
  Fold rise in salivary anti-GII.2 IgG 0.2 (0–1.9) .172
  Fold rise in salivary anti-GII.4 IgG 0.2 (.1–.5) < .001
  Fold rise in salivary anti-GII.6 IgG 1.9 (.7–5.1) .178
  Fold rise in salivary anti-GII.17 IgG 54.6 (5.4–552.6) < .001
Data from 175 cases with norovirus infection (149 from Lima cohort and 26 from the Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences 
for Child Health and Development [MAL-ED] cohort) and from 32 controls (MAL-ED cohort only) were included in this analysis. ORs and 95% CIs are derived from logistic regression models 
adjusting for each of the independent variables within the same model. Independent variables: log10 of fold rise in genotype-specific IgG mean fluorescence intensity of convalescent/second 
to the acute/first saliva samples. Dependent variables for reverse-transcription polymerase chain reaction–diagnosed negative/positive norovirus GI, GII.4, GII.6, and GII.17 infection status 
were coded as 0/1.
Abbreviations: CI, confidence interval; IgG, immunoglobulin G; OR, odds ratio.
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diagnosis in stool. The salivary assay sensitivity and specificity 
were highest for GII.4 and GII.6 infections using varying fold 
rise definitions as cutoff. The average time between acute and 
convalescent sample collection was highest among GI cases. 
Seven of the 11 GI cases that were misclassified by the salivary 
assay provided their convalescent sample on average 48  days 
(range, 44–90 days) after their acute sample was collected and 
may have been exposed to other genotypes during this time 
period, which may explain the lower sensitivity to detect GI 
cases. Most GII.17 cases that were misclassified by the salivary 
assay (13/17) showed a >3-fold rise in IgG against GII.2 (2/13 
[15%]), GII.4 (2/13 [15%]), or GII.6 (9/13 [69%]), suggesting 
cross-reactivity between salivary anti-GII.17 IgG and GII.2, 
GII.4, and GII.6 VLPs.
Limitations to this study included the following. First, we col-
lected 1 saliva sample from children in the Lima control group 
and could therefore not compare the assay performance between 
all cases and controls. The high number of cases, particularly of 
GII.4 cases, likely resulted in the negative associations observed 
between a rise in, for example, anti-GII.4 IgG and decreased 
odds of infection with GI. A  higher number of controls and 
more equally distributed genotypes among cases might have 
attenuated these statistically significant negative associations 
(odds ratios <1). The reported assay sensitivity and specificity 
describe the assay performance to detect the correct genotype 
among, for example, children with GII.4 infections compared 
to children with other genotype infections and a comparatively 
small number of controls (n = 32). Second, 12 children experi-
enced GII.12, GII.13, GII.20, or GII.22 infections. Samples from 
those children were included in the analysis (as non-GI, non-
GII.4, etc, cases) and thus contributed to the specificity of the 
assay, but VLPs for those genotypes were not available and we 
therefore could not include those genotypes into the multiplex 
assay. Two children who were included in the analysis experi-
enced coinfections with GI and GII, which likely decreased the 
assay performance as the assay interpretation only allowed for 1 
outcome. Third, we had a high number of GII.4 cases (n = 101), 
but only few GI, GII.6, and GII.17 cases and no GII.2 cases. The 
assay validation and our choice of the best threshold to discrim-
inate cases from noncases may therefore be influenced by the 
disproportionate distribution of the genotypes. Nonetheless, 
the average assay sensitivity and specificity to identify the cor-
rect infecting genotypes is high, particularly considering that 
the assay was validated using saliva samples from children who 
were on average 2 years old whose immune system may still be 
in the developing stage [29].
Other studies have shown that salivary norovirus immu-
noassays can correctly discriminate infected from uninfected 
individuals when comparing pre- to postchallenge samples 
from adult volunteers with PCR-confirmed infection status in 
a highly controlled setting (challenge study) and that salivary 
immunoassays can be applied to study asymptomatic norovirus 
infection in a tropical setting with unknown PCR diagnosis [16, 
17, 19]. However, participants in vaccine challenge studies are 
Table 4. Sensitivity and Specificity of the Salivary Norovirus Genotype-Specific Immunoglobulin G Assay Compared to Reverse-Transcription Polymerase 
Chain Reaction–Diagnosed Norovirus Genotype Outcome
Genotypea No. Sensitivity, no./No. (%) No. Specificity, no./No. (%)
(1) Infecting genotype defined as a fold rise that is larger than the 95th percentile of fold rise among controls
 GI 27 8/27 (30) 180 171/180 (95)
 GII.4 101 83/101 (82) 106 85/106 (80)
 GII.6 15 13/15 (87) 192 130/192 (68)
 GII.17 20 11/20 (55) 187 136/187 (73)
 Weighted mean 163 115/163 (71) 76%
(2) Infecting genotype defined as genotype with largest fold rise if >2
 GI 27 16/27 (62) 180 177/180 (98)
 GII.4 101 86/101 (85) 106 97/106 (92)
 GII.6 15 11/15 (73) 192 179/192 (93)
 GII.17 20 3/20 (15) 187 185/187 (99)
 Weighted mean 163 116/163 (71) 96%
(3) Infecting genotype defined as genotype with largest fold rise if >3
 GI 27 12/27 (44) 180 177/180 (98)
 GII.4 101 82/101 (81) 106 99/106 (93)
 GII.6 15 11/15 (73) 192 182/192 (95)
 GII.17 20 3/20 (15) 187 185/187 (99)
 Weighted mean 163 108/163 (66) 97%
Data from 175 cases with norovirus infection (149 from Lima cohort and 26 from the Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences 
for Child Health and Development [MAL-ED] cohort) and from 32 controls (MAL-ED cohort only) were included in this analysis. Cases were defined as (1) fold rise of convalescent to acute 
anti-norovirus genotype-specific immunoglobulin G (IgG) mean fluorescence intensity >95th percentile of the fold rise among controls; and (2) a >2-fold and (3) a >3-fold rise in salivary IgG 
against the norovirus genotype that elicited the highest immune response.
aPolymerase chain reaction–confirmed genotype from stool sample.
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routinely screened for past infection prior to enrollment and 
may not be representative of the population response in general, 
particularly in highly endemic areas. This is, to our knowledge, 
the first study to systematically validate a salivary norovi-
rus assay for its performance to (1) identify norovirus infec-
tion among children with known infection status in a highly 
endemic setting and (2) discriminate the 5 most common geno-
types using saliva samples from children <5 years of age.
Future studies should investigate if a salivary anti-norovirus 
IgA assay could be used to identify acute infection without the 
need for repeat sampling. Salivary immunoassays to monitor 
norovirus infections at the genotype level could be implemented 
in epidemiological studies in community settings, in outbreak 
investigations, and in high-risk settings such as schools or 
healthcare facilities to monitor transmission.
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